Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 29 entries
View as:

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT03057600 Org: User:
Start: 05/01/17 End: 11/25/19 Due: 11/25/20

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03357627 Org: User:
Start: 02/16/18 End: 08/03/21 Due: 08/03/22

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02944435 Org: User:
Start: 10/31/16 End: 11/30/16 Due: 11/30/17

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02071888 Org: User:
Start: 02/28/14 End: 04/30/16 Due: 04/30/17

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT02771626 Org: User:
Start: 08/01/16 End: 04/24/20 Due: 04/24/21

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02834247 Org: User:
Start: 08/12/16 End: 11/30/18 Due: 11/30/19

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02323113 Org: User:
Start: 03/09/15 End: 08/15/18 Due: 08/15/19

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02071927 Org: User:
Start: 03/31/14 End: 12/31/16 Due: 12/31/17

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03965845 Org: User:
Start: 06/25/19 End: 09/24/21 Due: 09/24/22

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Phase: N/A Priority: Normal
NCT ID: NCT04698681 Org: User:
Start: 01/19/21 End: 02/09/22 Due: 02/09/23

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03338881 Org: User:
Start: 05/10/18 End: 05/01/19 Due: 05/01/20

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02049957 Org: User:
Start: 02/13/14 End: 06/29/18 Due: 06/29/19

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT03359733 Org: User:
Start: 02/28/18 End: 08/20/19 Due: 08/20/20

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04265534 Org: User:
Start: 07/24/20 End: 02/09/22 Due: 02/09/23

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02756364 Org: User:
Start: 07/28/16 End: 11/25/19 Due: 11/25/20

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02197572 Org: User:
Start: 09/15/14 End: 02/28/19 Due: 02/28/20

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04279769 Org: User:
Start: 07/03/20 End: 11/23/21 Due: 11/23/22

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT05319028 Org: User:
Start: 06/23/22 End: 02/24/23 Due: 02/24/24

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03370302 Org: User:
Start: 01/17/18 End: 08/28/19 Due: 08/28/20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02071862 Org: User:
Start: 02/28/14 End: 03/31/19 Due: 03/31/20

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02000934 Org: User:
Start: 12/31/13 End: 06/29/21 Due: 06/29/22

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT03772288 Org: User:
Start: 04/03/19 End: 11/17/21 Due: 11/17/22

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04607512 Org: User:
Start: 10/05/20 End: 12/30/20 Due: 12/30/21

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03875313 Org: User:
Start: 05/20/19 End: 07/29/20 Due: 07/29/21

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

Phase: N/A Priority: Normal
NCT ID: NCT03163667 Org: User:
Start: 09/06/17 End: 06/01/20 Due: 06/01/21